Terrence Kearney - Theseus Pharmaceuticals Independent Director
| THRXDelisted Stock | USD 4.06 0.00 0.00% |
Director
Mr. Terrence Kearney is Directors of the company since October 2014. Mr. Kearney served on the Executive Management Team for Hospira Inc. a specialty pharmaceutical and medication delivery company from April 2004 to January 2011. Mr. Kearney served as Chief Operating Officer of Hospira from 2006 through 2010 and also Chief Financial Officer from 2004 to 2006. Mr. Kearney served as Vice President and Treasurer of Abbott Laboratories a pharmaceuticals and health care products company from 2001 through April 2004. From 1996 to 2001 Mr. Kearney was Divisional Vice President and Controller for Abbott International Division. Mr. Kearney also serves on the Board of Directors of Acceleron Pharma Inc. a biopharmaceutical company since July 2014 and was an Independent Director of Vertex Pharmaceutical Incorporated since May 17 2011. Mr. Kearney earned a B.A. in biology from the University of Illinois and an M.B.A. from the University of Denver. Mr. Kearney demonstrated leadership in his field his understanding of our industry and his senior management experience in several companies in our industry contributed to our conclusion that he should serve as a director. since 2014.
| Age | 60 |
| Tenure | 10 years |
| Phone | 857 400 9491 |
| Web | https://theseusrx.com |
Theseus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Theseus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Theseus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theseus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theseus to invest in growth at high rates of return. When we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Timothy Coughlin | aTyr Pharma | 51 | |
| Kathryn Falberg | Arcus Biosciences | 60 | |
| David Lacey | Arcus Biosciences | 67 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| David Beier | Arcus Biosciences | 69 | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| Andrew Hack | Mersana Therapeutics | 43 | |
| Paula CPA | Immuneering Corp | N/A | |
| Charles Rowland | Blueprint Medicines Corp | 59 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Kristen Hege | Mersana Therapeutics | 54 | |
| Yasunori Kaneko | Arcus Biosciences | 66 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| David McGirr | X4 Pharmaceuticals | 63 | |
| Amir Nashat | aTyr Pharma | 44 | |
| Willard Dere | Mersana Therapeutics | 64 | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Antoni Ribas | Arcus Biosciences | 53 | |
| Kristen Hege | Arcus Biosciences | 54 | |
| James Blair | aTyr Pharma | 78 | |
Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 |
Theseus Pharmaceuticals Leadership Team
Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick LePore, Independent Director | ||
| DPhil DPHIL, CoFounder Chairman | ||
| Nachu Narasimhan, VP Safety | ||
| Theodore Witek, Sr. VP of Corporate Partnerships, Clinical and Medical Affairs | ||
| WeiSheng Huang, CoFounder Chemistry | ||
| Catherine Friedman, Independent Director | ||
| James Tyree, Independent Director | ||
| Terrence Kearney, Independent Director | ||
| Michael Faerm, Chief Bus. Officer and Sr. VP | ||
| Barbara Duncan, Independent Director | ||
| Paul Pepe, Independent Director | ||
| George Abercrombie, Senior Vice President - Corporate Partnerships, Commercial | ||
| Timothy Clackson, Pres CEO | ||
| Len Rozamus, VP Operations | ||
| Eric dEsparbes, CFO and Sr. VP | ||
| Bradford Dahms, Chief officer | ||
| Alicja Januszewicz, VP Culture | ||
| Victor Rivera, VP CoFounder | ||
| Benjamin Enerson, VP Affairs | ||
| Michael Aguiar, CEO and President and Director | ||
| Kristine CPA, VP Controller | ||
| William Waltrip, Lead Independent Director | ||
| MA DPHIL, CoFounder Chairman | ||
| David MD, Chief Officer | ||
| William Shakespeare, CoFounder RD |
Theseus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (20.19 M) | |||
| Shares Outstanding | 44.65 M | |||
| Shares Owned By Insiders | 2.55 % | |||
| Shares Owned By Institutions | 93.28 % | |||
| Number Of Shares Shorted | 401.68 K | |||
| Price To Earning | 737.67 X | |||
| Price To Book | 0.81 X | |||
| EBITDA | (66.44 M) |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stocks Directory Find actively traded stocks across global markets |